Retinal Vein Occlusion Market to Advance at Moderate CAGR During the Forecast Period (2022-2032) – Estimates DelveInsight | Key Companies – Kodiak Sciences, Roche, AbbVie, Sunshine Guojian

June 05 07:08 2023
Retinal Vein Occlusion Market to Advance at Moderate CAGR During the Forecast Period (2022-2032) - Estimates DelveInsight | Key Companies - Kodiak Sciences, Roche, AbbVie, Sunshine Guojian
Delveinsight Business Research LLP
The Retinal Vein Occlusion market size in seven major markets was USD 2,378.1 million in 2021, which is further expected to increase by 2032 at a Compound Annual Growth Rate (CAGR) of 5.8% for the study period (2019–2032). The Retinal Vein Occlusion Market is anticipated to evolve immensely in the coming years owing to the expected launch of potential therapies assisted by an increase in the prevalent population of Retinal vein occlusion.

DelveInsight’s “Retinal Vein Occlusion Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Retinal Vein Occlusion market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Retinal Vein Occlusion drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Retinal Vein Occlusion treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Retinal Vein Occlusion: An Overview

Retinal vein occlusion (RVO), the second most common retinal vascular disorder after diabetic retinopathy, is an obstruction of the retinal venous system by thrombus formation and may involve the central, hemi-central, or branch retinal vein. The most common etiological factor is compression by adjacent atherosclerotic retinal arteries. Other possible causes are external compression or disease of the vein wall, e.g., vasculitis.

According to the affected area on the retinal surface, RVO can be classified into two types, central retinal vein occlusion (CRVO) which is the blockage of the main retinal vein, and branch retinal vein occlusion (BRVO) which is the blockage of one of the smaller branch veins. These are further classified into nonischemic and ischemic CRVO and major and macular BRVO. BRVO is 4–6 times more prevalent than CRVO.

Retinal Vein Occlusion Market Key Facts

  • Upcoming therapies such as KSI-301, Vabysmo, ONS-5010, and others have the potential to create a significant positive shift in the Retinal vein occlusion market size.

  • The United States accounts for the largest market size of Retinal vein occlusion, in comparison to EU5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.

  • Among the EU5 countries, Germany had the highest market size, with USD 141.0 million in 2021.

  • In the year 2021, the total Retinal Vein Occlusion prevalent cases were approximately 2,708,118 cases in the 7MM, which are expected to increase by 2032 at the CAGR of 1.0% during the study period (2019–2032).

  • Among EU-5 countries, the highest number of prevalent cases of Retinal vein occlusion was in Germany, (approximately 225,397 cases), in the year 2021, which is expected to increase by 2032. The lowest number of cases was observed in Spain.

  • In 2021, the total diagnosed prevalent cases of Retinal vein occlusion in the 7MM were approximately 1,518,208 cases, which is estimated to increase by 2032.

Retinal Vein Occlusion Market

Retinal Vein Occlusion Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Retinal Vein Occlusion pipeline therapies. It also thoroughly assesses the Retinal Vein Occlusion market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Retinal Vein Occlusion drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Retinal Vein Occlusion Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Retinal Vein Occlusion epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Retinal Vein Occlusion epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Retinal Vein Occlusion Epidemiology, Segmented as –

  • Total Prevalent Cases of RVO in the 7MM [2019–2032]

  • Total Diagnosed Prevalent Cases of RVO in the 7MM [2019–2032]

  • Total Age-specific Diagnosed Prevalent Cases of RVO in the 7MM [2019–2032]

  • Total Gender-specific Diagnosed Prevalent Cases of RVO in the 7MM [2019–2032]

  • Type-specific Diagnosed Prevalent Cases of RVO in the 7MM [2019–2032]

Retinal Vein Occlusion Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Retinal Vein Occlusion market or expected to be launched during the study period. The analysis covers the Retinal Vein Occlusion market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Retinal Vein Occlusion drugs based on their sale and market share.

The report also covers the Retinal Vein Occlusion pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Retinal Vein Occlusion companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Retinal Vein Occlusion Market Will Evolve and Grow by 2032 @

Retinal Vein Occlusion Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Retinal Vein Occlusion. Currently, Kodiak Sciences are leading the therapeutics market with its Retinal Vein Occlusion drug candidates in the mid to advanced stage of clinical development.

Retinal Vein Occlusion Companies Actively Working in the Therapeutics Market Include

AbbVie, Aerie Pharmaceuticals, Aerpio Therapeutics, AsclepiX Therapeutics, Chugai Pharmaceuticals, Clearside Biomedical, Eyevensys, Gene Signal, Graybug Vision, Hoffman-La-Roche, iRenix Medical, Inc., Kodiak Sciences Inc, Novartis, Ocular Therapeutix, Ocuphire Pharma, Outlook Therapeutics, Regeneron Pharmaceuticals, Ripple Therapeutics, Roche, Shanghai BDgene, Sunshine Guojian Pharmaceutical, Taiwan Liposome Company, The Emmes Company, and others.

Emerging and Marketed Retinal Vein Occlusion Therapies Covered in the Report Include:

  • KSI-301: Kodiak sciences

  • 601: Sunshine Guojian Pharmaceutical

  • IBE-814: Ripple Therapeutics

  • Lucentis (ranibizumab): Roche

  • Ozurdex (dexamethasone): AbbVie

  • KSI-301: Kodiak Sciences

  • Vabysmo (faricimab): Roche/Chugai Pharmaceuticals

  • TLC399 (ProDex): Taiwan Liposome Company

And Many Others

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Retinal Vein Occlusion Competitive Intelligence Analysis

4. Retinal Vein Occlusion Market Overview at a Glance

5. Retinal Vein Occlusion Disease Background and Overview

6. Retinal Vein Occlusion Patient Journey

7. Retinal Vein Occlusion Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Retinal Vein Occlusion Treatment Algorithm, Current Treatment, and Medical Practices

9. Retinal Vein Occlusion Unmet Needs

10. Key Endpoints of Retinal Vein Occlusion Treatment

11. Retinal Vein Occlusion Marketed Therapies

12. Retinal Vein Occlusion Emerging Drugs and Latest Therapeutic Advances

13. Retinal Vein Occlusion Seven Major Market Analysis

14. Attribute Analysis

15. Retinal Vein Occlusion Market Outlook (In US, EU5, and Japan)

16. Retinal Vein Occlusion Companies Active in the Market

17. Retinal Vein Occlusion Access and Reimbursement Overview

18. KOL Views on the Retinal Vein Occlusion Market

19. Retinal Vein Occlusion Market Drivers

20. Retinal Vein Occlusion Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Reports by DelveInsight

Cardiac Monitoring System Market

“Cardiac Monitoring System Market Insight, Competitive Landscape, and Market Forecast, 2028” report delivers an in-depth understanding of historical and forecasted Cardiac Monitoring System market size, share, and trends globally, which comprises North America, Europe, APAC, and RoW. Moreover, it covers the key companies, emerging products, and commercial & regulatory development, in the Cardiac Monitoring System Market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States